Abstract:

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. In pa-tients with poor prognosis, allogenic stem cell transplantation (ASCT) treatment is an alterna-tive. ASCT indications in CLL: Patients with refractory disease or early relapse (shorter than 12 months) after treatment with purine analogues, relapse within 24 months after achieving re-sponse with purine analogues/autologous stem cell transplantation or in patients with p53 anomalies. However, the indications have been revised after novel therapies achieved successful results in relapsed/refractory setting. In this study, we aimed to evaluate our CLL patients who underwent ASCT. Materials and Methods: Seven high-risk patients with CLL who were diagnosed at Ankara Uni-versity School of Medicine Department of Hematology between 2007-2015 and subsequently underwent ASCT at our Bone Marrow Transplantation Unit were evaluated retrospectively. Results: In post-transplant disease evaluation, 4/7 patients (57%) achieved complete remission and 3/7 patients (43%) did not respond. Acute graft versus host disease was detected in 2/7 (29%) patients while 3/7 (43%) patients were diagnosed with chronic graft versus host disease. Overall survival was 69 months (range, 19-121 months). Conclusion: Sustained response rates can be achieved with ASCT in high-risk CLL patients in long-term.

Keywords: